EGFR and non-small cell lung carcinoma: In one particular study, a mesenchymal drug-tolerant state has been observed to function as an important intermediate stage, enabling initially-EGFRT790M-negative non-small-cell lung cancer cells to acquire this “gatekeeper” mutation following treatment with EGFR inhibitors [71].